Dave Niel, Dawod Enad, Simmons Okeefe L
Division of Gastroenterology at HCA Florida Aventura Hospital, 20900 Biscayne Blvd, Aventura, FL 33180 USA.
Division of Gastroenterology, Weill Cornell Medicine, New York Presbyterian Hospital, 1305 York Avenue, 4th Floor, New York, NY 10021 USA.
Curr Treat Options Gastroenterol. 2023;21(2):172-184. doi: 10.1007/s11938-023-00420-6. Epub 2023 May 6.
Bariatric and metabolic endoscopic therapies provide an option for patients seeking clinically significant weight loss with fewer adverse events than conventional bariatric surgery. Our aims are to provide an overview of the current state of primary endoscopic treatment options for weight loss and to emphasize the importance of including these therapies when presenting weight loss options to qualified patients.
Bariatric endoscopy procedures are associated with a lower adverse event rate when compared to bariatric surgery and result in more weight loss than most existing pharmacotherapies approved by the Food and Drug Administration.
Sufficient evidence exists to implement bariatric endoscopic therapies-namely, the intragastric balloon and endoscopic sleeve gastroplasty-as safe and effective treatment options for weight loss when used in combination with lifestyle changes. However, bariatric endoscopy remains an underutilized option by weight management providers. Future studies are needed to identify patient and provider-level barriers to adopting endoscopic bariatric therapies as an option for the treatment of obesity.
减肥和代谢性内镜治疗为寻求显著临床体重减轻且不良事件少于传统减肥手术的患者提供了一种选择。我们的目的是概述当前减肥主要内镜治疗选择的现状，并强调在向符合条件的患者介绍减肥选择时纳入这些治疗的重要性。
与减肥手术相比，减肥内镜手术的不良事件发生率较低，且比美国食品药品监督管理局批准的大多数现有药物疗法导致更多的体重减轻。
有充分证据表明，减肥内镜治疗——即胃内球囊和内镜袖状胃成形术——与生活方式改变相结合时，作为安全有效的减肥治疗选择。然而，减肥内镜治疗仍然是体重管理提供者未充分利用的选择。未来需要开展研究，以确定患者和提供者层面采用内镜减肥治疗作为肥胖治疗选择的障碍。
